| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC1025 | Blapsin A | Natural Potent 14-3-3 inhibitor |
|
| DCC1026 | Blapsin B | Potent 14-3-3 inhibitor |
|
| DCC1027 | Bl-ei001 | Novel ERK inhibitor, inducing breast cancer cell apoptosis via mitochondrial pathway but independent on Ras/Raf/MEK pathway |
|
| DCC1028 | Calpain Inhibitor Ii | Inhibitor of calpain, cathepsin L and cathepsin B |
|
| DCC1029 | Azaguanine-8 | Inhibitor of Marburg virus (MARV) growth at noncytotoxic concentrations |
|
| DCC1030 | Bm-520 | Original TXA2 modulator, inhibiting the action of thromboxane A2 and 8-iso-prostaglandin F2alpha |
|
| DCC1031 | Bm-573 | Dual thromboxane synthase inhibitor and thromboxane receptor antagonist |
|
| DCC1032 | Bmc201725-9o | Novel potent EGFR inhibitor |
|
| DCC1033 | Bmd4503-2 | Novel LRP5/6-sclerostin interaction inhibitor, recovering the downregulated activity of the Wnt/β-catenin signaling pathway by competitive binding to the LRP5/6-sclerostin complex |
|
| DCC1034 | Bmh-22 | Novel inhibitor of RNA polymerase I, causing nucleolar stress and showing potent anticancer activity across many tumor types |
|
| DCC1035 | Bmi-1026 | Novel potent cyclin-dependent kinases (CDK) inhibitor, inducing a strong cell cycle alteration |
|
| DCC1036 | bml-259 | Potent and selective inhibitor of Cdk5/p25, protecting large population of cells against non-A |
|
| DCC1037 | Bml277 Acid | Metabolite of BML277 which is a selective checkpoint kinase 2 inhibitor |
|
| DCC1038 | Bmp Activator B06 | Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5 |
|
| DCC1039 | Bmp Activator B75 | Novel activator of BMP signaling, enhancing osteoblast differentiation, targeting HECT domain of ubiquitin ligase Smurf1, up-regulating the protein level of Smad1/5 |
|
| DCC1040 | Bmppb-32 | Novel Highly Selective LRRK2 Inhibitor |
|
| DCC1041 | Bms-1016 | Novel PD-L1 Inhibitor |
|
| DCC1042 | Bms1018 | Novel PD-1/PD-L1 Inhibitor |
|
| DCC1043 | Bms-124110 | Novel potent, selective inhibitor of AAK1 (adaptor associated kinase 1), having the appropriate combination of solubility and charge required for microiontophoresis |
|
| DCC1044 | Bms-180048 Fumarate | 5HT1B/1D agonist |
|
| DCC1045 | bms-180448 | Novel K channel opener; Glyburide-Reversible Cardioprotective Agent with Minimal Vasodilator Activity |
|
| DCC1046 | Bms-181184 | Novel antifungal and fungicidal agent |
|
| DCC1047 | BMS-182874 Hydrochloride | Quantity (mg or Unit) Unit Price ($/mg or $/Unit) Final Price 100 $13.95 Total: $1,395.00 50 $16.12 Total: $806.00 25 $18.91 Total: $472.75 10 $22.32 Total: $223.20 5 $26.35 Total: $131.75 |
|
| DCC1048 | Bms184394 Featured | Novel selective inhibitor of RARγ |
|
| DCC1049 | Bms-187745 | Squalene synthase inhibitor |
|
| DCC1050 | bms-189532 | Retinoic acid receptor (RAR) pan-antagonist |
|
| DCC1051 | Bms-193885 | Novel and selective neuropeptide Y1 receptor antagonist |
|
| DCC1052 | Bms-199264 Hydrochloride | Novel potent inhibitor of the ATP hydrolase activity of mitochondrial F1F0 ATP synthase |
|
| DCC1053 | Bms-201620 | Potent and selective β3 full agonist |
|
| DCC1054 | Bms-243117 | Potent and selective p56(lck) inhibitor |
|
